Randomized trial assessing the effects of ergocalciferol administration on circulating FGF23

1   **Supplementary figure legends:**

2

3   **Supplementary Figure 1.** Scatter plot with fitted regression lines of 25-hydroxyvitamin

4   D (25OHD) measured by liquid chromatography/tandem mass spectroscopy

5   (LC/MS/MS) (y-axis) and chemiluminescent immunoassay (CLIA) (x-axis). 25OHD

6   was measured on samples obtained at weeks 4-12 in the vitamin D (red asterisk) and

7   placebo (blue dot) groups. The regression equations for the two sets of data are $y = 0.35x$

8   $+ 25.58$ (vitamin D group – red dashed line) and $y = 0.45x + 12.40$ (placebo group-blue

9   solid line). Systeme International conversion factors: 25OHD (nM), 2.496.

10

11   **Supplementary Figure 2.** Mean ($\pm$ SE) 25-hydroxyvitamin D (25OHD) measured by

12   (A) liquid chromatography/tandem mass spectroscopy (LC/MS/MS) and (B)

13   chemiluminescent immunoassay (CLIA) at weeks 0, 4, 8, and 12 in the vitamin D (solid

14   line) and placebo (dashed line) groups (the horizontal gray line represents the lower limit

15   of normal for 25OHD levels). P value assesses change over time by repeated measures

16   analysis of variance (ANOVA) as compared to placebo. Systeme International

17   conversion factors: 25OHD (nM), 2.496.

18

19   **Supplementary Figure 3.** Mean ($\pm$ SE) (A) 25-hydroxyvitamin D_2 ($25OHD_2$) measured

20   by liquid chromatography/tandem mass spectroscopy (LC/MS/MS) and (B) $25OHD_3$

21   measured by LC/MS/MS at weeks 0, 4, 8, and 12 in the vitamin D (solid line) and

22   placebo (dashed line) groups. P value assesses change over time by repeated measures

Randomized trial assessing the effects of ergocalciferol administration on circulating FGF23

1   analysis of variance (ANOVA) as compared to placebo. Systeme International

2   conversion factors: 25OHD (nM), 2.496.

3

25OHD: LC/MS/MS vs. CLIA

25OHD by LC/MS/MS (ng/mL)

25OHD by CLIA (ng/mL)

Legend • • • Placebo ―― Placebo−Fit * * * RX - - - RX−Fit

Supplementary Fig. 1

A

LC/MS/MS

B

CLIA

P < 0.0001

Week

Supplementary Fig. 2

A

25OHD$_2$ measured by LC/MS/MS

P < 0.0001

B

25OHD$_3$ measured by LC/MS/MS

P < 0.0001

Week

Supplementary Fig. 3